Back
Amicus Therapeutics 10K Form
Sell
44
FOLD
Amicus Therapeutics
Last Price:
$9.81
Seasonality Move:
5.47%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
2024-05-09 | 10Q | FOLD/Amicus Therapeutics Quarterly |
2023-11-08 | 10Q | FOLD/Amicus Therapeutics Quarterly |
2023-08-08 | 10Q | FOLD/Amicus Therapeutics Quarterly |
2023-05-10 | 10Q | FOLD/Amicus Therapeutics Quarterly |
2022-11-07 | 10Q | FOLD/Amicus Therapeutics Quarterly |
2022-08-04 | 10Q | FOLD/Amicus Therapeutics Quarterly |
Receive FOLD News And Ratings
See the #1 stock for the next 7 days that we like better than FOLD
FOLD Financial Statistics
Sales & Book Value
Annual Sales: | $399.4M |
---|---|
Cash Flow: | $-23.3M |
Price / Cash Flow: | 0 |
Annual Sales: | $0.60 |
Price / Book: | 16.38 |
Profitability
EPS (TTM): | -0.34000 |
---|---|
Net Income (TTM): | $-104.7M |
Gross Margin: | $362M |
Return on Equity: | -71.17% |
Return on Assets: | -13.78% |
Amicus Therapeutics Earnings Forecast
Key Amicus Therapeutics Financial Ratios
-
The Gross Profit Margin over the past 21 years for FOLD is 90.65%.
-
The Selling, General & Administrative Expenses for FOLD have been equal to 68.93% of Gross Profit Margin.
-
The Research & Development expenses have been 38.16% of Revenue.
-
The Interest Expense is -33.08% of Operating Income.
-
The Net Earning history of FOLD is -37.96% of Total Revenues.
-
Per Share Earnings over the last 21 years have been positive in 11 years.
Amicus Therapeutics Stock Price Chart
Industry, Sector and Symbol
Stock Exchange: | NASDAQ |
---|---|
Industry: | Biotechnology |
Sector: | Health Care |
Current Symbol: | FOLD |
CUSIP: | 03152W |
Website: | amicusrx.com |
Debt
Debt-to-Equity Ratio: | 2.18 |
---|---|
Current Ratio: | 3.15 |
Quick Ratio: | 2.2 |
Price-to-Earnings
Trailing P/E Ratio: | 0 |
---|---|
Forward P/E Ratio: | 26.88 |
FOLD Technical Analysis vs Fundamental Analysis
Sell
44
Amicus Therapeutics (FOLD)
is a Sell
Is Amicus Therapeutics a Buy or a Sell?
-
Amicus Therapeutics stock is rated a SellThe current Amicus Therapeutics [FOLD] share price is $9.80. The Score for FOLD is 44, which is 12% below its historic median score of 50, and infers higher risk than normal.